OculomeX Health Ltd is a UK-based health technology company incorporated in October 2024. The company is developing an AI-driven software platform that uses retinal imaging to provide non-invasive, early detection of cardiovascular disease risk. The patented technology, licensed from the Universities of Leeds and Manchester, was developed by co-founder Professor Alejandro Frangi. OculomeX has built and validated a minimum viable product (MVP), received positive feedback from clinicians and users, and is now advancing the product toward commercial launch. The company aims to make early disease detection scalable and accessible globally through integration into opticians, pharmacies, and healthcare systems.